Xeris' G-Pen similar to standard kit in Phase III hypoglycemia

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) said its G-Pen glucagon injection rescue pen had comparable efficacy to a standard glucagon emergency kit in a double-blind, crossover Phase III trial to treat severe hypoglycemia in adult Type I diabetics. Data were presented at the American Diabetes Association meeting in Orlando.

The 80-patient, Canadian and U.S. trial’s primary endpoint was plasma glucose concentration of more than 70 mg/dL at 30 minutes. G-Pen led to plasma glucose levels of more than 70 mg/dL or at least a 20 mg/dL increase in plasma glucose in 97.4% of patients vs. 100% of patients who received the standard kit. G-Pen also rescued all patients from insulin-induced hypoglycemia without other rescue therapy...